Water-soluble bacterial glycan and oligosaccharide compositions for inhibiting viral replication and entry

Background

The ongoing challenge of viral infections, particularly those caused by persistent pathogens like HIV and HBV, continues to drive research in antiviral therapies. These viruses pose significant public health threats due to their ability to evade the immune system and establish chronic infections, leading to long-term health complications and increased transmission risk. The field of antiviral research seeks to develop strategies that not only suppress viral replication but also prevent infection at the cellular level, ideally without provoking adverse immune reactions or toxicity. There is a critical need for novel approaches that can enhance the body’s innate antiviral defenses, offering both therapeutic and preventative benefits against a broad spectrum of viral pathogens.

Current antiviral therapies, while effective to some extent, are often limited by several significant drawbacks. Many existing drugs target specific viral enzymes or processes, which can lead to the rapid emergence of drug-resistant viral strains. Additionally, some treatments may cause cytotoxicity or trigger unwanted immune responses, limiting their long-term use or suitability for prophylactic applications. Furthermore, most available therapies do not directly enhance the host’s intrinsic antiviral mechanisms, such as the upregulation of restriction factors that naturally inhibit viral replication and spread. As a result, there is an unmet need for safe, broad-spectrum antiviral agents that can bolster innate immunity without compromising host cell viability or provoking harmful side effects.

Technology

This technology utilizes water-soluble, heat-stable glycan strands and oligosaccharides derived from gram-positive bacterial cell walls, such as those from Streptococcus cristatus or Streptococcus mutans. These molecules, composed of two to 100 monosaccharide units—often alternating N-acetylglucosamine and N-acetylmuramic acid—are produced by isolating and enzymatically processing bacterial cell wall components to remove non-saccharide materials and generate the desired oligosaccharides. The resulting compounds are non-cytotoxic and non-immunogenic, making them suitable for therapeutic use. Their primary function is to enhance the expression of host restriction factors, specifically A3G and MX2, which are known to inhibit viral replication at multiple stages, including viral integration and infectivity. Additionally, these molecules can directly block viral entry into host cells, providing a multifaceted approach to preventing or treating viral infections such as HIV and HBV.

What differentiates this technology is its unique mechanism of action and safety profile. Unlike conventional antiviral agents that often target viral proteins directly and may lead to resistance or adverse immune responses, these bacterial-derived glycans work by upregulating the host’s intrinsic antiviral defenses, specifically A3G and MX2, which act at distinct points in the viral lifecycle. Their ability to directly block viral entry further broadens their protective effect. The molecules’ water solubility, heat stability, and lack of cytotoxicity or immunogenicity make them highly versatile and safe for a range of therapeutic applications. This combination of host-targeted action, broad-spectrum antiviral potential, and favorable safety characteristics sets this technology apart from traditional antiviral drugs and immunomodulators.

Benefits

• Water-soluble and heat-stable, ensuring ease of use and storage
• Non-cytotoxic and non-immunogenic, making it safe for therapeutic applications
• Enhances host restriction factors A3G and MX2 to inhibit viral replication
• Targets multiple stages of viral lifecycle, including early integration and late infectivity
• Directly blocks viral entry into host cells
• Potential to treat or prevent viral infections such as HIV and HBV

Applications

• HIV infection prevention therapies
• HBV antiviral treatment development
• Broad-spectrum antiviral drug design
• Topical antiviral prophylactic formulations

Additional info

Water-soluble, heat-stable glycan strands and oligosaccharides from gram-positive bacteria, comprising 2-100 monosaccharide units, are prepared by bacterial cell wall component isolation and enzymatic digestion. These non-cytotoxic, non-immunogenic molecules enhance host restriction factors A3G and MX2, inhibiting viral replication by targeting integration, infectivity, and entry. They offer a mechanism to treat or prevent viral infections like HIV and HBV.